NeoGenomics, Inc. Impairment of Intangible Assets (Excluding Goodwill)
NeoGenomics, Inc. (NEO) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-07-28
- NeoGenomics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-03-31 was $0.00.
- NeoGenomics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- NeoGenomics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- NeoGenomics, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2012 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-28 | $0.00 10-Q · filed 2026-07-28 | $0.00 derived: sum of 3 quarters · filed 2026-07-28 | $0.00 derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-28 | $0.00 derived: sum of 2 quarters · filed 2026-04-28 | $0.00 derived: sum of 3 quarters · filed 2026-04-28 | $11.40M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-04-28 | $0.00 derived: sum of 2 quarters · filed 2026-04-28 | $11.40M derived: sum of 3 quarters · filed 2026-07-28 | $11.40M 10-Q · filed 2026-04-28 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $11.40M derived: sum of 2 quarters · filed 2026-07-28 | $11.40M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $11.40M 10-Q · filed 2026-07-28 | $11.40M 10-Q · filed 2026-07-28 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $0.00 derived: sum of 2 quarters · filed 2013-10-30 | $0.00 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $0.00 10-Q · filed 2013-08-02 | ||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-13 | |||
| 2012-12-31 | $0.00 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |